Capstone Investment Advisors
ALDR

Capstone Investment Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Capstone Investment Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,263
Closed -$296K – 1037
2017
Q1 		$296K Buy
+14,263
New +$316K 0.01% 710

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Capstone Investment Advisors's ALDR Position: Q2 2017 in Review

Capstone Investment Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 14,263 shares — an estimated $296K sold.

Capstone Investment Advisors first reported a position in ALDR in Q1 2017 and held it in 1 quarter. The position peaked at $296K in Q1 2017. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Capstone Investment Advisors reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Capstone Investment Advisors sold 14,263 Alder Biopharmaceuticals shares in Q2 2017, an estimated $296K.
  • Capstone Investment Advisors first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Capstone Investment Advisors's Alder Biopharmaceuticals position peaked at $296K in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Capstone Investment Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.